1. Home
  2. XRP-USD vs SEPN Comparison

XRP-USD vs SEPN Comparison

Compare XRP-USD & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XRP-USD
  • SEPN
  • Stock Information
  • Founded
  • XRP-USD N/A
  • SEPN 2022
  • Country
  • XRP-USD
  • SEPN United States
  • Employees
  • XRP-USD N/A
  • SEPN N/A
  • Industry
  • XRP-USD
  • SEPN
  • Sector
  • XRP-USD
  • SEPN
  • Exchange
  • XRP-USD
  • SEPN NYSE
  • Market Cap
  • XRP-USD N/A
  • SEPN 453.2M
  • IPO Year
  • XRP-USD N/A
  • SEPN 2024
  • Fundamental
  • Price
  • XRP-USD $2.26
  • SEPN $11.40
  • Analyst Decision
  • XRP-USD
  • SEPN Strong Buy
  • Analyst Count
  • XRP-USD 0
  • SEPN 5
  • Target Price
  • XRP-USD N/A
  • SEPN $26.75
  • AVG Volume (30 Days)
  • XRP-USD N/A
  • SEPN 539.1K
  • Earning Date
  • XRP-USD N/A
  • SEPN 08-15-2025
  • Dividend Yield
  • XRP-USD N/A
  • SEPN N/A
  • EPS Growth
  • XRP-USD N/A
  • SEPN N/A
  • EPS
  • XRP-USD N/A
  • SEPN N/A
  • Revenue
  • XRP-USD N/A
  • SEPN $977,000.00
  • Revenue This Year
  • XRP-USD N/A
  • SEPN N/A
  • Revenue Next Year
  • XRP-USD N/A
  • SEPN $526.96
  • P/E Ratio
  • XRP-USD N/A
  • SEPN N/A
  • Revenue Growth
  • XRP-USD N/A
  • SEPN 108.76
  • 52 Week Low
  • XRP-USD N/A
  • SEPN $4.17
  • 52 Week High
  • XRP-USD N/A
  • SEPN $28.99
  • Technical
  • Relative Strength Index (RSI)
  • XRP-USD 55.66
  • SEPN N/A
  • Support Level
  • XRP-USD $2.15
  • SEPN N/A
  • Resistance Level
  • XRP-USD $2.32
  • SEPN N/A
  • Average True Range (ATR)
  • XRP-USD 0.10
  • SEPN 0.00
  • MACD
  • XRP-USD 0.02
  • SEPN 0.00
  • Stochastic Oscillator
  • XRP-USD 86.28
  • SEPN 0.00

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Share on Social Networks: